The chapter argues that since there is no conclusive evidence for a causal relationship between the issuance of compulsory licences (CL) for medicines and any fall in innovation or foreign direct investment (FDI) inflow, various other factors like predictability and market potential need to be taken into account for understanding the after-effects of a grant of CL. The chapter examines the trends in CLs after the Doha Declaration and carves out a case for adhering to transparent procedures for imparting some predictability to the process in order to mitigate losses from possible repercussions.